What is the recommended intranasal (IN) dose of midazolam for an adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Intranasal Midazolam Dosing for Adults

The recommended intranasal dose of midazolam for adults is 5-10 mg (0.2 mg/kg), with 10 mg being the standard bolus dose for most adult patients. 1

Dosing Guidelines

  • The standard intranasal bolus dose of midazolam for adults is 10 mg, which can be adjusted based on the patient's age and susceptibility to benzodiazepines 1
  • For more conservative dosing, 5 mg (0.2 mg/kg) is an effective dose that provides adequate sedation with fewer risks of respiratory depression 2, 3
  • Higher doses (0.3 mg/kg) have not shown additional benefits and may actually increase the risk of severe respiratory depression 2
  • The dose can be repeated if adequate sedation is not achieved with the initial administration 1

Pharmacokinetics of Intranasal Midazolam

  • Intranasal midazolam has a bioavailability of approximately 73-95%, making it an efficient non-invasive route of administration 1, 3
  • Peak plasma concentrations are reached within 10 minutes, indicating a rapid onset of action 1
  • In older adults (>65 years), the time to peak effect is approximately 32 minutes 3
  • Therapeutic concentrations (>30 ng/mL) can be achieved within 5 minutes of intranasal administration 4
  • The elimination half-life is approximately 1.9 hours for intranasal midazolam compared to 2.3 hours for intravenous administration 4

Clinical Considerations and Precautions

  • Dose reduction of 20% or more is indicated for patients older than 60 years and those with ASA physical status III or greater 5
  • Patients with hepatic or renal impairment require dose adjustments due to reduced midazolam clearance 5
  • When midazolam is used with an opioid, a synergistic interaction occurs that increases the risk of respiratory depression, necessitating a reduction in the midazolam dose 5
  • The major side effect of midazolam is respiratory depression, which can occur up to 30 minutes after administration 5
  • Local burning sensation in the nose is the most commonly reported adverse effect of intranasal administration (reported in 6 of 7 subjects in one study) 4

Advantages of Intranasal Route

  • Provides an alternative for patients who cannot tolerate intravenous cannulation 1
  • Particularly useful for claustrophobic patients undergoing MRI procedures, with a 97% success rate compared to 50% with oral administration 6
  • Avoids the risk of thrombophlebitis associated with intravenous diazepam 5
  • Offers superior amnestic properties compared to diazepam 5

Administration Technique

  • The medication should be administered as a spray into one or both nostrils 4
  • A concentrated formulation (50 mg/mL) allows for delivery of 5 mg per 0.1 mL (one spray) 4
  • For a 10 mg dose, administer one spray in each nostril or two sprays in one nostril 1, 4
  • Monitor vital signs including respiratory rate and oxygen saturation during and after administration 2, 3

Remember that midazolam has synergistic effects with opioids, which can significantly increase the risk of respiratory depression. Always have flumazenil available for reversal of benzodiazepine effects if needed, though be aware it may induce seizures in patients taking benzodiazepines for seizure control 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.